Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| MOVE | Movano | $16.20 | $9.23 | 132.43% | 37.8M | $6.3M | $4.67$55.00 |
| DRCT | Direct Digital | $4.07 | $1.76 | 76.19% | 99.9M | $3.0M | $1.58$80.85 |
| BNAI | Brand Engagement Network | $13.76 | $5.10 | 58.89% | 24.3M | $39M | $1.18$18.30 |
| QCLS | TNF Pharmaceuticals, Inc. | $5.48 | $1.41 | 34.64% | 17.8M | $17M | $2.50$137.99 |
| CHRS | Coherus Oncology | $2.07 | $0.48 | 29.87% | 14.1M | $192M | $0.71$2.17 |
| LIF | Life360 | $69.79 | $14.98 | 27.33% | 2.1M | $4.3B | $29.62$112.54 |
| ADAG | Adagene | $2.56 | $0.53 | 25.86% | 1.4M | $96M | $1.30$3.16 |
| GIBO | Gibo | $2.20 | $0.43 | 24.01% | 31.5M | $6.4M | $1.49$1,396.00 |
| UHG | United Homes Group | $2.18 | $0.42 | 23.86% | 1.3M | $104M | $0.99$4.81 |
| RVYL | Ryvyl | $6.45 | $1.21 | 23.09% | 12M | $5.4M | $4.50$81.55 |
Related Articles
Featured Article
This Biotech Is About to Eat AbbVie's Market Share, but Is It a Buy?
Alex Carchidi|Jun 16, 2023
Coherus' biosimilar to Humira could catapult the company to success.
Is There Any Hope for Atea Pharmaceuticals Stock?
Alex Carchidi|Nov 4, 2021
If its coronavirus pill project can't be salvaged, it'll be trouble for investors.
How Atea's Clinical Flop Shakes Up the COVID-19 Pill Market
Keith Speights and Brian Orelli, PhD|Oct 29, 2021
Merck and Pfizer could benefit from Atea's setback.
Was Atea Pharmaceutical's Flop Predictable?
Patrick Bafuma|Oct 26, 2021
Were warning signs there for investors all along?
3 Stocks to Consider if the October Stock Market Sell-Off Worsens
Keith Speights and Brian Orelli, PhD|Oct 17, 2021
These stocks could be attractive at discounted prices.
Can This Duo Outperform Merck and Ridgeback Biotherapeutics' COVID Treatment?
Patrick Bafuma|Oct 8, 2021
This partnership is showing early efficacy in the race for an oral COVID-19 treatment, but Atea and Roche are on their haunches.
This High-Risk, High-Reward Biotech Could Make COVID Less Deadly -- and Make Investors Money
Patrick Bafuma|Aug 4, 2021
An effective oral antiviral therapy for the coronavirus may be around the corner.
These 2 Coronavirus Stocks Could Soar in the First Half of 2021
Adria Cimino|Jan 26, 2021
This could be a key year for these companies' treatment candidates.
Coherus BioSciences Keeps Proving Wall Street Wrong
Maxx Chatsko|Aug 11, 2020
The biosimilar leader crushed it during the first half of 2020. Will it finally earn a higher market valuation?
2 Top Small-Cap Stocks to Buy Right Now
Maxx Chatsko|Jun 12, 2020
Volatile stock market or not, these two drug developers are well positioned for long-term success.
